Cited by 1,674Breast Cancer Treatment StudiesEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F·2010·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70257-6

Open this paper in CoChat — free account

Abstract

Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.Methods We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.Findings Patients were followed up for a median of 120 months (range 0-145); there were 24,522 woman-years of follow-up in the anastrozole group and 23,950 woman-years in the tamoxifen group. In the full study population, there were significant improvements in the anastrozole group compared with the tamoxifen group for disease-free survival (hazard ratio [HR] 0·91, 95% CI 0·83-0·99; p=0·04), time to recurrence (0·84, 0·75-0·93; p=0·001), and time to distant recurrence (0·87, 0·77-0·99; p=0·03). For hormone-receptor-positive patients, the results were also significantly in favour of the anastrozole group for disease-free survival (HR 0·86, 95% CI 0·78-0·95; p=0·003), time to recurrence (0·79, 0·70-0·89; p=0·0002), and time to distant recurrence (0·85, 0·73-0·98; p=0·02). In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (2·7% at 5 years and 4·3% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment completion (HR 0·81, 95% CI 0·67-0·98; p=0·03), although the carryover benefit was smaller after 8 years. There was weak evidence of fewer deaths after recurrence with anastrozole compared with tamoxifen treatment in the hormone-receptor-positive subgroup (HR 0·87, 95% CI 0·74-1·02; p=0·09), but there was little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4). Fractures were more frequent during active treatment in patients receiving anastrozole than those receiving tamoxifen (451 vs 351; OR 1·33, 95% CI 1·15-1·55; p<0·0001), but were similar in the post-treatment follow-up period (110 vs 112; OR 0·98, 95% CI 0·74-1·30; p=0·9). Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). No differences in non-breast cancer causes of death were apparent and the incidence of other cancers was similar between groups (425 vs 431) and continue to be higher with anastrozole for colorectal (66 vs 44) and lung cancer (51 vs 34), and lower for endometrial cancer (six vs 24), melanoma (eight vs 19), and ovarian cancer (17 vs 28). No new safety concerns were reported.Interpretation These data confirm the long-term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70257-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Self-citation
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Self-citation
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989
Self-citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Self-citation

Show all 27 references

Sorted by citations

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S. P., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,853
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Fang, X., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,242
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F. M., Poortmans, P. M., Rutgers, E. J. T., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,660
Cells of origin in cancer
Visvader, J. E. (2011) · Nature · doi:10.1038/nature09781 · Cited by 1,524
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B. J. K., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,356
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,280
The benefits and harms of breast cancer screening: an independent review
Screening, T. I. U. P. O. B. C., Marmot, M. G., Altman, D. G., Cameron, D., Dewar, J. A., Thompson, S. G., & Wilcox, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.177 · Cited by 1,153
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martín, M., Shao, Z. M., Zhang, Q. Y., Rodriguez, J. L. M., Campone, M., Hamilton, E. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,056
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic‐Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,024
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz‐Flores, S., Dent, S. F., Kondapalli, L., Ky, B., Okwuosa, T. M., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 883
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Dowsett, M., Cuzick, J. M., Ingle, J. N., Coates, A. S., Forbes, J., Bliss, J. M., Buyse, M. E., Baum, M., Buzdar, A. U., Colleoni, M. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1274 · Cited by 809
Self-citation
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Malin, J. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 799
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Cuzick, J. M., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L. A., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 741
Self-citation
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Dowsett, M., Cuzick, J. M., Wale, C., Forbes, J., Mallon, E., Salter, J., Quinn, E., Dunbier, A. K., Baum, M., Buzdar, A. U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4798 · Cited by 724
Self-citation
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Control of mammary stem cell function by steroid hormone signalling
Asselin-Labat, M.-L., Vaillant, F., Sheridan, J. M., Pal, B., Wu, D., Simpson, E. R., Yasuda, H., Smyth, G. K., Martin, T. J., Lindeman, G. J., et al. (2010) · Nature · doi:10.1038/nature09027 · Cited by 693
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
Amir, E., Šeruga, B., Niraula, S., Carlsson, L., & Ocaña, A. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr242 · Cited by 629
Comparison of PAM50 Risk of Recurrence Score With Onco type DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Dowsett, M., Šestak, I., López‐Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., Ferree, S., Storhoff, J. J., Schaper, C., & Cuzick, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1558 · Cited by 621
Self-citation
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R. E., von Minckwitz, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62292-8 · Cited by 590
Self-citation
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balić, M., Haslbauer, F., Melbinger‐Zeinitzer, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60995-3 · Cited by 567
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
Miller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 533
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
The BIG 1-98 Collaborative Group (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810818 · Cited by 498
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 553
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F. M., Poortmans, P. M., Thompson, A. M., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 465
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 425
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R. R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 414
Breast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · 癌症：英文版 · doi:10.1002/cac2.12358 · Cited by 453
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco‐Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Li, J., Moore, N. L. T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 406
A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition
Sinn, H., & Kreipe, H. H. (2013) · Breast Care · doi:10.1159/000350774 · Cited by 405
Aromatase, aromatase inhibitors, and breast cancer
Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.001 · Cited by 401
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Sgroi, D. C., Šestak, I., Cuzick, J. M., Zhang, Y., Schnabel, C. A., Schroeder, B. E., Erlander, M. G., Dunbier, A. K., Sidhu, K., López‐Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Self-citation
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M., Hosseini‐Fard, S. R., Babolhavaeji, K., Akbari, S. K. A., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 416
Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer
Henry, N. L., Azzouz, F., Desta, Z., Li, L., Nguyen, A., Lemler, S. M., Hayden, J. A., Tarpinian, K., Yakim, E., Flockhart, D. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0261 · Cited by 388
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J. A. L., Malone, C. M., McLaughlin, R. P., & Kerin, M. J. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 397
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
van de Velde, C. J., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.-M., Paridaens, R., Markopoulos, C., Hozumi, Y., Hille, E. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62312-4 · Cited by 372
Endocrine resistance in breast cancer – An overview and update
Clarke, R. C., Tyson, J. J., & Dixon, J. M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.035 · Cited by 367
Cancer, Physical Activity, and Exercise
Brown, J. C., Winters‐Stone, K. M., Lee, A. C., & Schmitz, K. H. (2012) · Comprehensive physiology · doi:10.1002/cphy.c120005 · Cited by 416
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
Self-citation
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
Coleman, R. E., BOER, R. D., Eidtmann, H., Llombart‐Cussac, A., Davidson, N. G. P., Neven, P., von Minckwitz, G., Sleeboom, H. P., Forbes, J., Barrios, C. H., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds277 · Cited by 339
Self-citation
Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy
King, T. A., Sakr, R. A., Patil, S. N., Gurevich, I. Y., Stempel, M. M., Sampson, M. R., & Morrow, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4041 · Cited by 332
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. A. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 520
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
Šestak, I., Buus, R., Cuzick, J. M., Dubsky, P. C., Kronenwett, R., Denkert, C., Ferree, S., Sgroi, D. C., Schnabel, C. A., Baehner, F. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5524 · Cited by 320
Self-citation
Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
Šestak, I., Distler, W., Forbes, J., Dowsett, M., Howell, A., & Cuzick, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2021 · Cited by 312
Self-citation
Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
Makubate, B., Donnan, P. T., Dewar, J. A., Thompson, A. M., & McCowan, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.116 · Cited by 298
Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR
Monticciolo, D. L., Newell, M. S., Moy, L. P., Lee, C. S., & Destounis, S. V. (2023) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2023.04.002 · Cited by 300
Tamoxifen Resistance in Breast Cancer
Chang, M.-S. (2012) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.20.3.256 · Cited by 205
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
Visvanathan, K., Chlebowski, R. T., Hurley, P. A., Col, N. F., Ropka, M. E., Collyar, D. E., Morrow, M., Runowicz, C. D., Pritchard, K. I., Hagerty, K. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5179 · Cited by 285
Self-citation
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Hadji, P., Aapro, M., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J., Zillikens, M. C., Glüer, C., de Villiers, T., Baber, R., et al. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.03.001 · Cited by 290
Guidelines for the diagnosis, prevention and management of osteoporosis
Rossini, M., Adámi, S., Bertoldo, F., Diacinti, D., Gatti, D., Giannini, S., Giusti, A., Malavolta, N., Minisola, S., Osella, G., et al. (2016) · Reumatismo · doi:10.4081/reumatismo.2016.870 · Cited by 279
Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer
Liao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 299
Early breast cancer
Benson, J. R., Jatoi, I., Keisch, M. E., Esteva, F. J., Makris, A., & Jordan, V. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60316-0 · Cited by 276
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Demark‐Wahnefried, W., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 265
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Rae, J. M., Drury, S., Hayes, D. F., Stearns, V., Thibert, J. N., Haynes, B. P., Salter, J., Šestak, I., Cuzick, J. M., & Dowsett, M. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs126 · Cited by 259
Self-citation
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
García-Becerra, R., Santos, N. D., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 261
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
Šestak, I., Cuzick, J. M., Dowsett, M., López‐Knowles, E., Filipits, M., Dubsky, P. C., Cowens, J. W., Ferree, S., Schaper, C., Fesl, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6894 · Cited by 250
Self-citation
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Gnant, M., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balić, M., Haslbauer, F., Melbinger‐Zeinitzer, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30862-3 · Cited by 239
Declining Incidence of Contralateral Breast Cancer in the United States From 1975 to 2006
Nichols, H. B., de González, A. B., Lacey, J. V., Rosenberg, P. S., & Anderson, W. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7395 · Cited by 238
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
Cuzick, J. M., Šestak, I., Forbes, J., Dowsett, M., Cawthorn, S., Mansel, R. E., Loibl, S., Bonanni, B., Evans, D. G., & Howell, A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32955-1 · Cited by 242
Self-citation
Breast Cancer: Major Risk Factors and Recent Developments in Treatment
Majeed, W., Aslam, B., Javed, I., Khaliq, T., Muhammad, F., Ali, A., & Raza, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.8.3353 · Cited by 231
New Strategies in Estrogen Receptor–Positive Breast Cancer
Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1823 · Cited by 230
Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
Reid, D. M., Doughty, J., Eastell, R., Heys, S. D., Howell, A., McCloskey, E. V., Powles, T. J., Selby, P. L., & Coleman, R. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.007 · Cited by 229
Self-citation
Adjuvant and neoadjuvant therapy for breast cancer
Shien, T., & Iwata, H. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz213 · Cited by 238
Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial
Poznak, C. H. V., Hannon, R. A., Mackey, J. R., Campone, M., Apffelstaedt, J., Clack, G., Barlow, D. H., Makris, A., & Eastell, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5902 · Cited by 225
Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
Šestak, I., Dowsett, M., Zabaglo, L. A., López‐Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt244 · Cited by 226
Self-citation
Preventive therapy for breast cancer: a consensus statement
Cuzick, J. M., DeCensi, A., Arun, B. K., Brown, P. H., Castiglione, M. M., Dunn, B., Forbes, J., Glaus, A., Howell, A., von Minckwitz, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70030-4 · Cited by 225
Self-citation
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G., & Murphy, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00245 · Cited by 224
Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients
Bedrosian, I., Hu, C., & Chang, G. J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq018 · Cited by 217
A review of clinical aspects of breast cancer
Libson, S., & Lippman, M. E. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.852971 · Cited by 218
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis
Šestak, I., Cuzick, J. M., Sapunar, F. J., Eastell, R., Forbes, J., Bianco, A. R., & Buzdar, A. U. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70182-7 · Cited by 208
Self-citation
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
Ingle, J. N., Schaid, D. J., Goss, P. E., Liu, M., Mushiroda, T., Chapman, J.-A. W., Kubo, M., Jenkins, G. D., Batzler, A. J., Shepherd, L. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5064 · Cited by 207
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Buus, R., Šestak, I., Kronenwett, R., Denkert, C., Dubsky, P. C., Krappmann, K., Scheer, M., Petry, C., Cuzick, J. M., & Dowsett, M. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw149 · Cited by 207
Self-citation
Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers
Brown, S. B., & Hankinson, S. E. (2014) · Steroids · doi:10.1016/j.steroids.2014.12.013 · Cited by 210
Molecular mechanisms and clinical management of cancer bone metastasis
Wang, M., Xia, F., Wei, Y., & Wei, X. (2020) · Bone Research · doi:10.1038/s41413-020-00105-1 · Cited by 204
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
Forbes, J., Šestak, I., Howell, A., Bonanni, B., Bundred, N. J., Lévy, C., von Minckwitz, G., EIERMANN, W., Neven, P., Stierer, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01129-0 · Cited by 198
Self-citation
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Dowsett, M., Šestak, I., Regan, M. M., Dodson, A. R., Viale, G., Thurlimann, B. J. K., Colleoni, M. A., & Cuzick, J. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4258 · Cited by 195
Self-citation
Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial
Bartlett, J. M. S., Brookes, C. L., Robson, T., van de Velde, C. J. �., Billingham, L. J., Campbell, F., Grant, M., Hasenburg, A., Hille, E. T. M., Kay, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3677 · Cited by 193
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
Hadji, P., Aapro, M., Body, J. J., Bundred, N. J., Brufsky, A., Coleman, R. E., Gnant, M., Guise, T. A., & Lipton, A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr017 · Cited by 192
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
Cuzick, J. M., Šestak, I., Cella, D. F., & Fallowfield, L. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70259-6 · Cited by 188
Self-citation
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio, M., Sun, Z., Price, K. N., Castiglione‐Gertsch, M., Hawle, H., Thurlimann, B. J. K., Mouridsen, H. T., Campone, M., Forbes, J., Paridaens, R., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp033 · Cited by 185
Self-citation
Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
Yin, W., Jiang, Y., Shen, Z., Shao, Z., & Lu, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021030 · Cited by 184
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
Coleman, R. L., Gnant, M., Morgan, G. J., & Clézardin, P. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs263 · Cited by 189
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
Harrod, A., Fulton, J., Nguyen, V. T. M., Periyasamy, M., Ramos-Garcia, L., Lai, C.-F., Metodieva, G., de Giorgio, A., WILLIAMS, R., Santos, D. B., et al. (2016) · Oncogene · doi:10.1038/onc.2016.382 · Cited by 180
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
Fred Saad, C., Adachi, J. D., Brown, J. P., Canning, L. A., Gelmon, K. A., Josse, R. G., & Pritchard, K. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.4184 · Cited by 182
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Goldvaser, H., Barnes, T. A., Šeruga, B., Cescon, D. W., Ocaña, A., Ribnikar, D., & Amir, E. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx141 · Cited by 181
Outcomes after Total Skin-sparing Mastectomy and Immediate Reconstruction in 657 Breasts
Peled, A. W., Foster, R. D., Stover, A. C., Itakura, K., Ewing, C. A., Alvarado, M. D., Hwang, E. S., & Esserman, L. J. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2362-y · Cited by 180
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
Osborne, C. K., Neven, P., Dirix, L. Y., Mackey, J. R., Robert, J., Underhill, C. R., Schiff, R., Gutiérrez, C., Migliaccio, I., Anagnostou, V., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1869 · Cited by 179
Hormone replacement therapy and the risk of breast cancer
Narod, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.110 · Cited by 179
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1 -Mutant Breast Tumors in Preclinical Models
Weir, H. M., Bradbury, R. H., Lawson, M., Rabow, A. A., Buttar, D., Callis, R. J., Curwen, J., de Almeida, C., Ballard, P. G., Hulse, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2357 · Cited by 178
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells
Martinez‐Outschoorn, U., Goldberg, A. F., Zhao, L., Ko, Y., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R. G., Howell, A., Sotgia, F., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.10.17780 · Cited by 180
Self-citation
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 188
Breast Cancer in the Elderly
Crivellari, D., Aapro, M., Leonard, R. C., von Minckwitz, G., Brain, E. G. C., Goldhirsch, A., Veronesi, A., & Muss, H. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2079 · Cited by 168
Tackling the Diversity of Triple-Negative Breast Cancer
Turner, N. C., & Reis-Filho, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0915 · Cited by 175
Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor–Positive Metastatic Breast Cancer
Guttery, D. S., Page, K., Hills, A., Woodley, L., Marchese, S. D., Rghebi, B., Hastings, R. K., Luo, J., Pringle, J. H., Stebbing, J., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.238717 · Cited by 170

Authors: Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F.
Affiliations: University of London (GB)
Cancer Research UK (GB)
The University of Texas MD Anderson Cancer Center (US)
Royal Marsden Hospital (GB)
University of Newcastle Australia (AU)
Corresponding author: Cuzick, Jack
ORCID: Cuzick, Jack
Baum, Michael
Buzdar, Aman
Howell, Anthony
Dowsett, Mitch
Forbes, John F
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2010-12
Volume: 11
Issue: 12
Pages: 1135-1141
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70257-6
OpenAlex: W2112780046
Cited by: 1,674
References: 27
Citations by year: 2026: 21 · 2025: 35 · 2024: 50 · 2023: 54 · 2022: 63 · 2021: 64 · 2020: 85 · 2019: 66 · 2018: 85 · 2017: 98 · 2016: 101 · 2015: 116 · 2014: 125 · 2013: 148 · 2012: 121
FWCI: 51.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: AstraZeneca
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords: anastrozole, tamoxifen, adjuvant endocrine therapy, early breast cancer, postmenopausal women, disease-free survival, time to recurrence, distant recurrence, hormone receptor-positive breast cancer, contralateral breast cancer, overall survival, fracture risk, long-term outcomes, ATAC trial, aromatase inhibitors, selective estrogen receptor modulators, breast cancer recurrence
MeSH terms: Anastrozole, Administration, Oral, Breast Neoplasms, Female, Follow-Up Studies, Humans, Neoplasm Staging, Nitriles, Tamoxifen, Triazoles, Treatment Outcome, Chemotherapy, Adjuvant, Postmenopause, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks